Skip to main content

ResMed| guidance

  • RMD · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$239.53+0.27%Close 13 Nov 2026 · Market value $33.91B

In its results release of 29 Oct 2026 (Q1 FY2027), ResMed| gave 1 forecast in figures, among them EPS (adjusted) of $12.00 to $12.25 for FY2027.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q1 FY2027 results, 29 Oct 2026

MeasurePeriodGuidanceAs stated
EPS · AdjustedFY2027$12.00 to $12.25Non-GAAP Diluted EPS $12.00 - $12.25

Source: the company's earnings release.

Guidance against results last two years

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
EPS · AdjustedFY2027$12.00 to $12.25Given once—To come

RMD in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.